Hide Assignment Information | ||||||||||
Turnitin™ | ||||||||||
This assignment will be submitted to Turnitin™. | ||||||||||
Instructions | ||||||||||
CTA Prototype Assignment Weight: 20% of Final Grade As discussed in class, in order for a clinical trial to be conducted in Canada, a Clinical Trial Application must be filed and approved by Health Canada before it can begin. As a regulatory affairs associate working for a large multinational pharmaceutical company, you have been asked to prepare a CTA for a new oncology product named “Sheridanumab”. The proposed study is for “An Open-label, Multicenter, Single-arm, Phase II Study of Sheridanumab in Patients with Germline BRCA1/2 Mutation and Platinum-sensitive Recurrent Ovarian Cancer”. You have previously held a pre-CTA meeting with Health Canada and have been given the green light to proceed with a CTA. 1. Create a prototype of your CTA, listing all relevant documents that you would need to file and what CTD section it would go in. If a CTA section does not apply, please indicate N/A. Please organize your Modules using the following tabular format:
2. Indicate what guidance document(s) you used to determine how to build your CTA prototype. 3. Summarize the differences between a CTA and IND.
General Instructions: | ||||||||||
I have 6 questions that I need answered PLEASE DO NOT USE ARTIFICIAL INTELLENCE 1. The Individuals with Disabilities Act (IDEA) requires IEP teams
I have 6 questions that I need answered PLEASE DO NOT USE ARTIFICIAL INTELLENCE 1. The Individuals with Disabilities Act (IDEA) requires IEP teams to consider the effect of a given disability on a child’s performance and identify each child’s unique strengths, preferences, interests, and needs to develop specially designed